Free Trial
→ Federal Reserve Reveals Disturbing New Plan To Control Your Money (From Weiss Ratings) (Ad)tc pixel Free IPSC Stock Alerts

Century Therapeutics (IPSC) Financials

Century Therapeutics logo
$1.40 +0.03 (+1.81%)
Closing price 03:59 PM Eastern
Extended Trading
$1.38 -0.02 (-1.42%)
As of 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Century Therapeutics

Annual Income Statements for Century Therapeutics

This table shows Century Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -54 -96 -131 -137 -127 -9.58
Consolidated Net Income / (Loss)		 -54 -96 -131 -137 -127 -9.58
Net Income / (Loss) Continuing Operations		 -54 -96 -131 -137 -127 -9.58
Total Pre-Tax Income 		-54 -96 -131 -135 -125 -9.65
Total Operating Income		 -54 -95 -134 -147 -138 -17
Total Gross Profit		 0.00 0.00 5.20 2.24 6.59 109
Total Revenue		 0.00 0.00 5.20 2.24 6.59 109
Operating Revenue		 - 0.00 5.20 2.24 6.59 109
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 54 95 139 149 145 126
Selling, General & Admin Expense		 9.50 19 32 35 33 24
Research & Development Expense		 44 76 107 98 107 96
Impairment Charge		 - - 0.00 16 4.33 6.76
Total Other Income / (Expense), net		 0.65 -1.80 2.99 12 13 7.62
Interest & Investment Income		 - - - 13 13 7.35
Other Income / (Expense), net		 0.65 -1.80 2.99 -0.38 0.35 0.28
Income Tax Expense		 0.00 0.04 0.09 1.88 1.79 -0.07
Basic Earnings per Share		 ($7.16) ($2.96) ($2.27) ($2.30) ($1.61) ($0.14)
Weighted Average Basic Shares Outstanding		 7.48M 32.39M 57.76M 59.31M 78.65M 86.56M
Diluted Earnings per Share		 ($7.16) ($2.96) ($2.96) ($2.30) ($1.61) ($0.14)
Weighted Average Diluted Shares Outstanding		 7.48M 32.39M 32.39M 59.31M 78.65M 86.56M
Weighted Average Basic & Diluted Shares Outstanding		 - 58.82M 59.17M 64.82M 86.05M 179.72M

Quarterly Income Statements for Century Therapeutics

This table shows Century Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -39 -28 -31 -31 -36 77 -33 -34 -19 -22 -35
Consolidated Net Income / (Loss)		 -39 -28 -31 -31 -36 77 -33 -34 -19 -22 -35
Net Income / (Loss) Continuing Operations		 -39 -28 -31 -31 -36 77 -33 -34 -19 -22 -35
Total Pre-Tax Income 		-40 -28 -31 -31 -34 0.00 0.00 -34 -19 0.00 0.00
Total Operating Income		 -44 -31 -35 -35 -37 74 -35 -36 -21 -24 -37
Total Gross Profit		 0.27 0.86 0.77 0.79 4.17 109 0.00 0.00 - 0.00 0.00
Total Revenue		 0.27 0.86 0.77 0.79 4.17 109 0.00 0.00 - 0.00 0.00
Operating Revenue		 0.27 0.86 0.77 0.79 4.17 109 0.00 0.00 - 0.00 0.00
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 44 32 36 36 41 35 35 36 21 24 37
Selling, General & Admin Expense		 8.59 8.74 8.31 8.35 7.75 8.41 7.81 6.84 0.96 6.58 5.79
Research & Development Expense		 23 23 27 27 29 27 27 23 20 17 20
Other Operating Expenses / (Income)		 - - - - - - 0.00 - - - 11
Total Other Income / (Expense), net		 3.50 3.25 3.57 3.56 2.99 2.38 2.12 1.70 1.41 2.04 1.98
Interest & Investment Income		 3.51 3.24 3.58 3.31 2.88 2.42 2.01 1.61 1.31 2.02 1.98
Other Income / (Expense), net		 -0.02 0.01 -0.01 0.25 0.11 -0.04 0.11 0.10 0.10 0.02 -0.01
Basic Earnings per Share		 ($0.66) ($0.45) ($0.38) ($0.37) ($0.41) $0.89 ($0.38) ($0.40) ($0.25) ($0.11) ($0.17)
Weighted Average Basic Shares Outstanding		 59.31M 62.30M 82.09M 84.70M 78.65M 86.02M 86.24M 86.46M 86.56M 193.47M 205.78M
Diluted Earnings per Share		 - ($0.45) ($0.38) ($0.37) - $0.89 ($0.38) ($0.40) ($0.25) ($0.11) ($0.17)
Weighted Average Diluted Shares Outstanding		 59.31M 62.30M 82.09M 84.70M 78.65M 86.10M 86.24M 86.46M 86.56M 193.47M 205.78M
Weighted Average Basic & Diluted Shares Outstanding		 64.82M 82.85M 84.72M 85.03M 86.05M 86.16M 86.39M 87.31M 179.72M 180.35M 181.08M

Annual Cash Flow Statements for Century Therapeutics

This table details how cash moves in and out of Century Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -16 30 28 -37 12 3.80
Net Cash From Operating Activities		 -41 -89 14 -88 -110 -104
Net Cash From Continuing Operating Activities		 -41 -89 14 -88 -110 -104
Net Income / (Loss) Continuing Operations		 -54 -96 -131 -137 -127 -9.58
Consolidated Net Income / (Loss)		 -54 -96 -131 -137 -127 -9.58
Depreciation Expense		 1.40 3.75 8.44 13 13 13
Amortization Expense		 0.09 0.31 0.30 -3.89 -4.81 -2.36
Non-Cash Adjustments To Reconcile Net Income		 6.62 6.35 13 30 16 9.59
Changes in Operating Assets and Liabilities, net		 4.19 -3.58 123 9.16 -8.41 -115
Net Cash From Investing Activities		 -23 -298 -13 61 47 108
Net Cash From Continuing Investing Activities		 -23 -298 -13 61 47 108
Purchase of Property, Plant & Equipment		 -9.83 -45 -31 -14 -0.15 -0.85
Acquisitions		 -4.72 - - 0.00 -9.61 0.00
Purchase of Investments		 -50 -330 -254 -209 -120 -51
Sale and/or Maturity of Investments		 42 77 271 284 177 160
Net Cash From Financing Activities		 48 418 27 -9.73 75 0.17
Net Cash From Continuing Financing Activities		 48 418 27 -9.73 75 0.17
Repayment of Debt		 -0.14 - 0.00 -10 57 0.00
Issuance of Common Equity		 0.00 222 27 0.52 18 0.17
Cash Income Taxes Paid		 - 0.01 0.00 2.52 0.50 3.89

Quarterly Cash Flow Statements for Century Therapeutics

This table details how cash moves in and out of Century Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 -7.98 -0.51 -4.50 11 5.78 -6.57 4.95 -0.91 6.34 -11 -1.76
Net Cash From Operating Activities		 -26 -30 -27 -28 -24 -35 -28 -26 -16 -25 -20
Net Cash From Continuing Operating Activities		 -26 -30 -27 -28 -25 -35 -28 -26 -16 -25 -20
Net Income / (Loss) Continuing Operations		 -39 -28 -31 -31 -36 77 -33 -34 -19 -22 -35
Consolidated Net Income / (Loss)		 -39 -28 -31 -31 -36 77 -33 -34 -19 -22 -35
Depreciation Expense		 3.55 3.23 3.46 3.30 3.32 3.22 3.20 3.13 3.55 3.00 2.62
Amortization Expense		 -3.98 -1.12 -1.34 -1.32 -1.03 -0.85 -0.65 -0.51 -0.35 -0.21 -0.15
Non-Cash Adjustments To Reconcile Net Income		 17 4.77 1.04 3.69 6.85 2.66 3.10 7.02 -3.19 0.02 12
Changes in Operating Assets and Liabilities, net		 -2.91 -9.07 0.71 -2.78 1.85 -116 -0.70 -0.80 3.09 -6.43 0.69
Net Cash From Investing Activities		 19 12 -34 39 31 28 33 25 22 -113 18
Net Cash From Continuing Investing Activities		 19 12 -34 39 31 28 33 25 22 -113 18
Purchase of Property, Plant & Equipment		 -0.98 -0.54 -0.27 0.80 -0.15 -0.48 -0.32 -0.20 0.14 -0.58 -0.69
Purchase of Investments		 -9.69 -35 -54 -13 -17 -15 -9.67 -11 -16 -141 -16
Sale and/or Maturity of Investments		 29 47 30 52 48 43 43 36 38 29 34
Net Cash From Financing Activities		 -0.36 18 57 0.27 -0.60 0.12 - - 0.05 127 0.31
Net Cash From Continuing Financing Activities		 -0.36 18 57 0.27 -0.60 0.12 - - 0.05 127 0.31
Issuance of Common Equity		 -0.36 18 0.10 0.27 -0.60 0.12 - - 0.05 0.20 0.35

Annual Balance Sheets for Century Therapeutics

This table presents Century Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 107 437 487 361 353 224
Total Current Assets		 79 228 320 177 194 121
Cash & Equivalents		 27 56 84 47 58 62
Short-Term Investments		 49 166 231 125 131 55
Prepaid Expenses		 2.26 4.77 4.00 4.26 4.76 3.66
Plant, Property, & Equipment, net		 15 58 83 72 62 50
Total Noncurrent Assets		 13 151 84 112 97 53
Long-Term Investments		 1.05 136 52 89 31 0.00
Intangible Assets		 - - - 0.00 34 34
Other Noncurrent Operating Assets		 12 15 32 23 32 19
Total Liabilities & Shareholders' Equity		 107 437 487 361 353 224
Total Liabilities		 33 41 184 176 192 65
Total Current Liabilities		 12 16 30 18 130 20
Short-Term Debt		 0.00 1.04 6.50 - 0.00 3.76
Accounts Payable		 8.08 7.60 5.45 2.74 3.08 4.77
Accrued Expenses		 4.03 6.04 9.84 10 17 12
Customer Deposits		 0.00 0.98 0.87 0.58 0.08 0.02
Total Noncurrent Liabilities		 21 25 154 158 62 45
Noncurrent Deferred & Payable Income Tax Liabilities		 - - - 0.00 4.37 4.30
Other Noncurrent Operating Liabilities		 12 17 39 47 58 40
Total Equity & Noncontrolling Interests		 -106 396 303 185 161 159
Total Preferred & Common Equity		 -106 396 303 185 161 159
Total Common Equity		 -106 396 303 185 161 159
Common Stock		 218 785 824 840 943 951
Retained Earnings		 -292 -388 -519 -656 -782 -792
Accumulated Other Comprehensive Income / (Loss)		 -0.00 -0.65 -2.46 0.11 0.32 0.03

Quarterly Balance Sheets for Century Therapeutics

This table presents Century Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 398 349 416 389 316 285 245 327 287
Total Current Assets		 174 200 203 206 170 160 138 139 125
Cash & Equivalents		 55 47 41 53 52 57 56 51 50
Short-Term Investments		 114 145 155 146 113 99 77 84 70
Prepaid Expenses		 4.20 7.80 7.08 7.90 4.51 4.33 4.96 4.24 5.06
Plant, Property, & Equipment, net		 82 69 69 65 60 57 54 48 34
Total Noncurrent Assets		 142 80 144 117 86 68 53 140 128
Long-Term Investments		 115 58 73 47 21 2.69 0.00 82 77
Intangible Assets		 - - 33 34 34 34 34 34 34
Other Noncurrent Operating Assets		 27 22 32 32 32 31 19 24 16
Total Liabilities & Shareholders' Equity		 398 349 416 389 316 285 245 327 287
Total Liabilities		 178 171 194 193 75 75 68 62 55
Total Current Liabilities		 20 16 19 20 15 15 22 14 15
Short-Term Debt		 0.00 - - - - - 8.34 1.94 0.00
Accounts Payable		 5.93 3.43 3.36 2.60 3.57 3.21 2.62 3.15 4.82
Accrued Expenses		 9.93 7.53 11 13 11 12 11 8.48 10
Customer Deposits		 0.71 0.49 0.35 0.21 0.00 0.02 0.02 0.00 0.00
Total Noncurrent Liabilities		 158 155 175 173 61 60 46 48 40
Noncurrent Deferred & Payable Income Tax Liabilities		 - - 3.37 3.50 4.37 4.37 4.37 4.30 4.30
Other Noncurrent Operating Liabilities		 46 44 62 60 56 55 42 44 35
Total Equity & Noncontrolling Interests		 219 178 222 196 240 210 176 265 232
Total Preferred & Common Equity		 219 178 222 196 240 210 176 265 232
Total Common Equity		 219 178 222 196 240 210 176 265 232
Common Stock		 837 862 937 941 946 948 949 1,079 1,081
Retained Earnings		 -616 -684 -715 -746 -706 -738 -773 -814 -848
Accumulated Other Comprehensive Income / (Loss)		 -1.30 -0.24 -0.31 0.76 0.31 0.08 0.06 -0.59 -0.69

Annual Metrics And Ratios for Century Therapeutics

This table displays calculated financial ratios and metrics derived from Century Therapeutics' official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 54,641,380.00 58,974,247.00 59,834,968.00 - 87,307,091.00
DEI Adjusted Shares Outstanding		 0.00 54,641,380.00 58,974,247.00 59,834,968.00 - 87,307,091.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -1.75 -2.22 -2.28 - -0.11
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% -57.01% 194.81% 1,556.76%
EBITDA Growth		 0.00% -78.96% -31.82% -12.84% 6.16% 95.17%
EBIT Growth		 0.00% -81.55% -35.34% -12.30% 6.22% 87.67%
NOPAT Growth		 0.00% -76.04% -41.05% -9.50% 5.74% 87.50%
Net Income Growth		 0.00% -78.86% -36.64% -4.38% 7.40% 92.43%
EPS Growth		 0.00% 58.66% 0.00% 22.30% 30.00% 91.30%
Operating Cash Flow Growth		 0.00% -115.66% 115.79% -728.72% -24.66% 5.68%
Free Cash Flow Firm Growth		 0.00% 0.00% 107.51% -1,088.71% -44.02% -1.20%
Invested Capital Growth		 0.00% 666.90% -214.74% -41.77% 23.79% 177.58%
Revenue Q/Q Growth		 0.00% 0.00% 11.14% -10.17% 145.40% -3.68%
EBITDA Q/Q Growth		 0.00% 0.00% -0.11% -13.72% -2.23% 73.73%
EBIT Q/Q Growth		 0.00% 0.00% -1.48% -9.94% -4.19% 49.45%
NOPAT Q/Q Growth		 0.00% 0.00% -4.15% -7.68% 4.48% 49.05%
Net Income Q/Q Growth		 0.00% 0.00% -2.74% -5.98% 2.56% 63.81%
EPS Q/Q Growth		 0.00% 0.00% -2,790.91% 0.00% 0.00% 53.33%
Operating Cash Flow Q/Q Growth		 0.00% -14.29% 11.45% -3.91% 1.79% 7.27%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 6.18% 1.91% 6.61%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.98% -18.52% -19.92% -12.24%
Profitability Metrics		 - - - - - -
Gross Margin		 0.00% 0.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 0.00% 0.00% -2,348.57% -6,164.43% -1,962.22% -5.73%
Operating Margin		 0.00% 0.00% -2,574.17% -6,556.87% -2,096.48% -15.82%
EBIT Margin		 0.00% 0.00% -2,516.66% -6,574.00% -2,091.11% -15.57%
Profit (Net Income) Margin		 0.00% 0.00% -2,518.41% -6,115.12% -1,920.87% -8.78%
Tax Burden Percent		 100.00% 100.04% 100.07% 101.40% 101.43% 99.30%
Interest Burden Percent		 100.61% 99.07% 100.00% 91.74% 90.56% 56.77%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -73.04% -40.81% -37.46% -56.07% -73.14% -5.98%
Cash Return on Invested Capital (CROIC)		 0.00% -401.84% 0.00% 0.00% 0.00% -255.41%
Operating Return on Assets (OROA)		 0.00% 0.00% -28.32% -34.68% -38.60% -5.89%
Return on Assets (ROA)		 0.00% 0.00% -28.34% -32.26% -35.46% -3.32%
Return on Common Equity (ROCE)		 105.97% -25.19% -37.46% -56.07% -73.14% -5.98%
Return on Equity Simple (ROE_SIMPLE)		 50.35% -24.18% -43.25% -73.98% -78.44% 0.00%
Net Operating Profit after Tax (NOPAT)		 -38 -66 -94 -103 -97 -12
NOPAT Margin		 0.00% 0.00% -1,801.92% -4,589.81% -1,467.54% -11.07%
Net Nonoperating Expense Percent (NNEP)		 -23.59% -14.14% -10.55% -11.02% -12.40% 1.50%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -55.52% -59.92% -7.43%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 612.75% 1,552.84% 503.19% 21.99%
R&D to Revenue		 0.00% 0.00% 2,061.42% 4,371.81% 1,627.62% 87.64%
Operating Expenses to Revenue		 0.00% 0.00% 2,674.17% 6,656.87% 2,196.48% 115.82%
Earnings before Interest and Taxes (EBIT)		 -53 -97 -131 -147 -138 -17
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -52 -93 -122 -138 -129 -6.25
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 0.00 2.19 1.00 1.08 0.53 0.55
Price to Tangible Book Value (P/TBV)		 0.00 2.19 1.00 1.08 0.68 0.70
Price to Revenue (P/Rev)		 0.00 0.00 58.19 88.88 13.03 0.80
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 52.37 10.93 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.13 0.03 0.03 0.00 0.00 0.02
Long-Term Debt to Equity		 0.13 0.02 0.01 0.00 0.00 0.00
Financial Leverage		 -0.92 -0.89 -1.01 -1.27 -1.39 -1.04
Leverage Ratio		 1.46 1.16 1.32 1.74 2.06 1.80
Compound Leverage Factor		 1.46 1.15 1.32 1.59 1.87 1.02
Debt to Total Capital		 11.61% 2.45% 3.27% 0.00% 0.00% 2.31%
Short-Term Debt to Total Capital		 0.00% 0.26% 2.08% 0.00% 0.00% 2.31%
Long-Term Debt to Total Capital		 11.61% 2.19% 1.19% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 216.62% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -128.23% 97.55% 96.73% 100.00% 100.00% 97.69%
Debt to EBITDA		 -0.19 -0.11 -0.08 0.00 0.00 -0.60
Net Debt to EBITDA		 1.30 3.77 2.92 0.00 0.00 18.14
Long-Term Debt to EBITDA		 -0.19 -0.10 -0.03 0.00 0.00 0.00
Debt to NOPAT		 -0.26 -0.15 -0.11 0.00 0.00 -0.31
Net Debt to NOPAT		 1.78 5.25 3.81 0.00 0.00 9.38
Long-Term Debt to NOPAT		 -0.26 -0.13 -0.04 0.00 0.00 0.00
Altman Z-Score		 -0.94 11.25 -0.67 -2.68 -3.88 -3.37
Noncontrolling Interest Sharing Ratio		 245.08% 38.28% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 6.51 14.57 10.72 9.92 1.50 5.97
Quick Ratio		 6.25 14.24 10.58 9.68 1.46 5.79
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -108 8.08 -80 -115 -116
Operating Cash Flow to CapEx		 -420.04% -197.91% 45.92% -643.19% -71,516.23% -12,249.53%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 -147.91 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 -163.61 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 -189.04 0.00 0.00
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.00 0.01 0.01 0.02 0.38
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.07 0.03 0.10 1.95
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 6.18 47 -54 -77 -59 46
Invested Capital Turnover		 0.00 0.00 -1.49 -0.03 -0.10 -16.58
Increase / (Decrease) in Invested Capital		 0.00 41 -102 -23 18 104
Enterprise Value (EV)		 324 518 -55 -63 -134 -27
Market Capitalization		 211 867 303 199 86 87
Book Value per Share		 ($14.22) $7.25 $5.13 $3.09 $1.90 $1.82
Tangible Book Value per Share		 ($14.22) $7.25 $5.13 $3.09 $1.50 $1.43
Total Capital		 83 406 313 185 161 163
Total Debt		 9.64 9.94 10 0.00 0.00 3.76
Total Long-Term Debt		 9.64 8.90 3.74 0.00 0.00 0.00
Net Debt		 -67 -349 -357 -262 -220 -113
Capital Expenditures (CapEx)		 9.83 45 31 14 0.15 0.85
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -9.07 -9.34 -19 -14 -125 -13
Debt-free Net Working Capital (DFNWC)		 67 214 296 159 64 104
Net Working Capital (NWC)		 67 212 290 159 64 101
Net Nonoperating Expense (NNE)		 16 29 37 34 30 -2.51
Net Nonoperating Obligations (NNO)		 -67 -349 -357 -262 -220 -113
Total Depreciation and Amortization (D&A)		 1.49 4.05 8.74 9.15 8.49 11
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% -367.22% -608.05% -1,897.45% -11.74%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 5,701.21% 7,120.72% 975.40% 95.54%
Net Working Capital to Revenue		 0.00% 0.00% 5,576.15% 7,120.72% 975.40% 92.10%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($2.96) ($2.27) ($2.30) ($1.61) ($0.14)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 32.39M 57.76M 59.31M 78.65M 86.56M
Adjusted Diluted Earnings per Share		 $0.00 ($2.96) ($2.27) ($2.27) ($1.61) ($0.14)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 32.39M 57.76M 57.76M 78.65M 86.56M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 58.82M 59.17M 64.82M 86.05M 179.72M
Normalized Net Operating Profit after Tax (NOPAT)		 -38 -66 -94 -91 -94 -7.35
Normalized NOPAT Margin		 0.00% 0.00% -1,801.92% -4,077.26% -1,421.57% -6.74%
Pre Tax Income Margin		 0.00% 0.00% -2,516.66% -6,030.96% -1,893.70% -8.84%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 -272.09 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 -189.97 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 -297.53 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 -215.40 0.00 0.00
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Century Therapeutics

This table displays calculated financial ratios and metrics derived from Century Therapeutics' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 59,834,968.00 64,817,863.00 82,847,375.00 84,715,961.00 - 86,045,033.00 86,158,758.00 86,389,098.00 87,307,091.00 179,722,750.00 180,354,809.00
DEI Adjusted Shares Outstanding		 59,834,968.00 64,817,863.00 82,847,375.00 84,715,961.00 - 86,045,033.00 86,158,758.00 86,389,098.00 87,307,091.00 179,722,750.00 180,354,809.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.66 -0.43 -0.38 -0.37 - 0.89 -0.38 -0.40 -0.22 -0.12 -0.19
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -48.56% -50.29% 678.79% 434.46% 1,456.72% 12,667.72% -100.00% -100.00% 0.00% -100.00% 0.00%
EBITDA Growth		 -60.28% 0.42% -2.05% -0.92% 21.07% 362.12% 1.99% -2.59% 50.27% -127.28% -6.46%
EBIT Growth		 -43.58% 3.03% 1.41% 3.02% 15.07% 336.88% 0.62% -4.31% 44.72% -131.92% -5.73%
NOPAT Growth		 -31.39% 2.41% 0.92% 2.35% 14.80% 336.92% 0.26% -3.84% 44.60% -131.93% -5.37%
Net Income Growth		 -24.35% 10.24% 6.26% 4.57% 8.44% 372.82% -4.27% -10.24% 46.84% -128.27% -6.17%
EPS Growth		 0.00% 0.00% 32.14% 32.73% 0.00% 297.78% 0.00% -8.11% 39.02% -112.36% 55.26%
Operating Cash Flow Growth		 -14.51% -3.52% -41.98% -107.58% 7.65% -14.46% -0.95% 9.70% 33.63% 27.04% 28.12%
Free Cash Flow Firm Growth		 -110.10% 106.15% 6.94% -172.77% -460.88% -2,809.54% -307.64% -212.43% -167.33% 84.35% 92.40%
Invested Capital Growth		 -41.77% -52.15% 11.02% 24.67% 23.79% 175.86% 208.08% 206.01% 177.58% -8.96% -31.56%
Revenue Q/Q Growth		 81.08% 219.03% -9.82% 2.59% 427.43% 2,516.59% -100.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -37.02% 33.98% -11.86% 0.26% -7.16% 319.25% -141.82% -4.40% 48.05% -20.27% -63.22%
EBIT Q/Q Growth		 -22.92% 28.51% -11.08% 0.66% -7.64% 299.41% -146.60% -4.27% 42.95% -15.13% -54.38%
NOPAT Q/Q Growth		 -22.84% 28.46% -11.01% -0.10% -7.17% 298.95% -132.71% -4.21% 42.82% -14.65% -54.23%
Net Income Q/Q Growth		 -20.41% 28.77% -11.21% -0.06% -15.52% 312.25% -142.50% -5.78% 44.29% -12.87% -59.62%
EPS Q/Q Growth		 0.00% 0.00% 15.56% 2.63% 0.00% 317.07% -142.70% -5.26% 37.50% 56.00% -54.55%
Operating Cash Flow Q/Q Growth		 -92.18% -15.32% 9.64% -3.66% 14.50% -42.93% 20.31% 7.28% 37.16% -57.13% 21.49%
Free Cash Flow Firm Q/Q Growth		 46.51% 134.78% -1,196.33% -33.72% -9.99% -68.04% -134.96% -2.49% 5.89% 90.16% 19.90%
Invested Capital Q/Q Growth		 -18.52% 6.61% 33.98% -3.09% -19.92% 192.95% -5.93% 1.11% -12.24% 9.07% -29.28%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 -16,495.90% -3,413.68% -4,234.50% -4,116.56% -836.39% 70.08% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 -16,329.10% -3,661.87% -4,507.78% -4,398.10% -893.67% 67.95% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 -16,334.70% -3,660.58% -4,509.34% -4,366.50% -891.16% 67.91% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 -14,700.75% -3,282.11% -4,047.60% -3,947.66% -864.60% 70.13% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 97.84% 100.00% 100.07% 99.97% 105.18% 0.00% 100.00% 100.00% 99.65% 0.00% 0.00%
Interest Burden Percent		 91.98% 89.66% 89.70% 90.43% 92.25% 0.00% 94.18% 95.55% 93.63% 0.00% 0.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -56.07% -58.66% -55.95% -62.61% -73.14% -10.49% 0.00% 0.00% -5.98% -42.67% -49.65%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% -273.69% -236.90% -240.01% -255.41% -145.13% -151.84%
Operating Return on Assets (OROA)		 -86.18% -12.46% -22.09% -29.83% -16.45% 23.50% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 -77.56% -11.18% -19.83% -26.96% -15.96% 24.27% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -56.07% -58.66% -55.95% -62.61% -73.14% -10.49% 0.00% 0.00% -5.98% -42.67% -49.65%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -75.03% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -31 -22 -24 -24 -26 52 -24 -25 -14 -17 -26
NOPAT Margin		 -11,430.37% -2,563.31% -3,155.45% -3,078.67% -625.57% 47.56% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -2.83% -2.14% -2.41% -2.60% -4.14% 11.31% -3.87% -4.95% -2.83% -2.53% -5.05%
Return On Investment Capital (ROIC_SIMPLE)		 -16.58% -12.32% -10.95% -12.44% -16.17% 21.60% -11.56% -13.69% -8.89% -6.22% -11.00%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 3,204.85% 1,022.57% 1,077.30% 1,055.88% 185.86% 7.70% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 8,692.54% 2,739.30% 3,530.48% 3,442.23% 704.10% 24.35% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 16,429.10% 3,761.87% 4,607.78% 4,498.10% 993.67% 32.05% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -44 -31 -35 -35 -37 74 -35 -36 -21 -24 -37
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -44 -29 -33 -33 -35 77 -32 -33 -17 -21 -34
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.08 1.52 0.95 0.74 0.53 0.17 0.23 0.24 0.55 1.53 1.90
Price to Tangible Book Value (P/TBV)		 1.08 1.52 1.15 0.92 0.68 0.20 0.27 0.30 0.70 1.76 2.23
Price to Revenue (P/Rev)		 88.88 197.77 103.46 53.95 13.03 0.36 0.42 0.38 0.80 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.85 6.96
Enterprise Value to Revenue (EV/Rev)		 0.00 15.38 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.05 0.02 0.01 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.27 -1.26 -1.21 -1.27 -1.39 -1.04 -0.99 -0.99 -1.04 -0.79 -0.80
Leverage Ratio		 1.74 1.77 1.77 1.89 2.06 1.59 1.62 1.70 1.80 1.27 1.29
Compound Leverage Factor		 1.60 1.59 1.59 1.71 1.90 0.00 1.53 1.63 1.69 0.00 0.00
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4.51% 2.31% 0.73% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4.51% 2.31% 0.73% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 95.49% 97.69% 99.27% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.35 -0.60 -0.02 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5.23 18.14 2.08 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.35 -0.31 -0.02 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5.24 9.38 2.67 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -1.73 -1.45 -1.49 -1.95 -2.94 -1.07 -2.63 -3.50 -3.43 0.68 0.75
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 9.92 12.44 10.62 10.39 1.50 11.70 10.72 6.25 5.97 10.25 8.28
Quick Ratio		 9.68 11.95 10.25 10.00 1.46 11.39 10.43 6.03 5.79 9.94 7.94
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -7.92 2.76 -30 -40 -44 -75 -123 -126 -119 -12 -9.36
Operating Cash Flow to CapEx		 -2,676.53% -5,611.87% -10,313.96% 0.00% -15,729.22% -7,289.05% -8,704.10% -13,120.00% 0.00% -4,325.68% -2,857.93%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.01 0.00 0.00 0.01 0.02 0.35 0.33 0.36 0.38 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.03 0.02 0.03 0.04 0.10 1.79 1.81 1.90 1.95 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -77 -72 -48 -49 -59 55 51 52 46 50 35
Invested Capital Turnover		 -0.03 -0.02 -0.04 -0.05 -0.10 -13.22 59.43 76.94 -16.58 0.00 0.00
Increase / (Decrease) in Invested Capital		 -23 -25 5.88 16 18 127 99 101 104 -4.89 -16
Enterprise Value (EV)		 -63 21 -58 -100 -134 -145 -110 -81 -27 191 245
Market Capitalization		 199 271 211 145 86 41 48 43 87 406 442
Book Value per Share		 $3.09 $2.74 $2.68 $2.31 $1.90 $2.79 $2.44 $2.04 $1.82 $1.47 $1.29
Tangible Book Value per Share		 $3.09 $2.74 $2.22 $1.86 $1.50 $2.40 $2.04 $1.65 $1.43 $1.28 $1.10
Total Capital		 185 178 222 196 161 240 210 185 163 267 232
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 8.34 3.76 1.94 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -262 -250 -270 -245 -220 -186 -159 -124 -113 -215 -197
Capital Expenditures (CapEx)		 0.98 0.54 0.27 -0.80 0.15 0.48 0.32 0.20 -0.14 0.58 0.69
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -14 -8.27 -12 -12 -125 -9.99 -11 -8.73 -13 -7.39 -10
Debt-free Net Working Capital (DFNWC)		 159 184 184 186 64 155 145 124 104 127 110
Net Working Capital (NWC)		 159 184 184 186 64 155 145 116 101 125 110
Net Nonoperating Expense (NNE)		 8.76 6.15 6.88 6.87 9.97 -25 8.28 9.14 4.72 5.07 8.98
Net Nonoperating Obligations (NNO)		 -262 -250 -270 -245 -220 -186 -159 -124 -113 -215 -197
Total Depreciation and Amortization (D&A)		 -0.43 2.11 2.12 1.98 2.29 2.37 2.55 2.62 3.20 2.79 2.47
Debt-free, Cash-free Net Working Capital to Revenue		 -608.05% -603.50% -591.92% -444.06% -1,897.45% -8.70% -9.31% -7.70% -11.74% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 7,120.72% 13,412.26% 9,026.20% 6,934.41% 975.40% 135.01% 127.25% 109.43% 95.54% 0.00% 0.00%
Net Working Capital to Revenue		 7,120.72% 13,412.26% 9,026.20% 6,934.41% 975.40% 135.01% 127.25% 102.07% 92.10% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.66) ($0.45) ($0.38) ($0.37) ($0.41) $0.89 ($0.38) ($0.40) ($0.25) ($0.11) ($0.17)
Adjusted Weighted Average Basic Shares Outstanding		 59.31M 62.30M 82.09M 84.70M 78.65M 86.02M 86.24M 86.46M 86.56M 193.47M 205.78M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($0.38) ($0.37) $0.00 $0.89 ($0.38) ($0.40) ($0.25) ($0.11) ($0.17)
Adjusted Weighted Average Diluted Shares Outstanding		 59.31M 82.85M 82.09M 84.70M 78.65M 86.10M 86.24M 86.46M 86.56M 193.47M 205.78M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 64.82M 82.85M 84.72M 85.03M 86.05M 86.16M 86.39M 87.31M 179.72M 180.35M 181.08M
Normalized Net Operating Profit after Tax (NOPAT)		 -31 -22 -24 -24 -26 52 -24 -21 -14 -17 -26
Normalized NOPAT Margin		 -11,430.37% -2,563.31% -3,155.45% -3,078.67% -625.57% 47.56% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 -15,025.00% -3,281.99% -4,044.75% -3,948.67% -822.05% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Century Therapeutics (NASDAQ: IPSC) remains a development-stage biotechnology company with no recurring operating revenue in the latest quarter. Its financial statements show persistent operating losses and cash burn, although recent cost reductions and a debt-free balance sheet provide some financial flexibility.

Revenue and profitability: Q2 2026 revenue was $0, compared with $0 in Q2 2025 and Q2 2024. The company reported a $34.6 million net loss in Q2 2026, wider than the $21.6 million loss in Q1 2026 and the $32.5 million loss in Q2 2025. The Q1 2025 results included a restated $109.2 million revenue benefit, but that appears to have been a non-recurring item rather than evidence of an established revenue stream.

Operating expenses were $36.5 million in Q2 2026. Research and development spending increased sequentially to $19.6 million from $17.1 million in Q1, but remained below the $26.9 million reported in Q2 2025 and $27.2 million in Q2 2024. Selling, general and administrative expense declined to $5.8 million from $6.6 million in Q1 and $7.8 million a year earlier. However, $11.1 million of other operating expenses contributed to the wider quarterly loss.

Cash flow and liquidity: Operating cash outflow was $19.8 million in Q2 2026, an improvement from $25.3 million in Q1 2026 and $27.6 million in Q2 2025. Nevertheless, IPSC has generated negative operating cash flow in each comparable quarter provided, indicating that operations are not yet self-funding. Investing activities provided $17.8 million in Q2, primarily because investment maturities exceeded new investment purchases; this is not a recurring operating source of cash.

At June 30, 2026, IPSC held $49.6 million in cash, $70.1 million in short-term investments and $77.5 million in long-term investments, or approximately $197.2 million of cash and investments. That compares with approximately $158.9 million at June 30, 2025, but is below the approximately $269.6 million held at June 30, 2024. At the latest quarterly operating burn rate, this liquidity could provide a substantial runway, although clinical spending and financing needs can change significantly.

Balance sheet and shareholder considerations: Total liabilities declined to $54.7 million from $61.8 million in Q1 2026 and $74.8 million in Q2 2025. Short-term debt was eliminated by Q2 after the company repaid $126.4 million of debt during Q1. However, total assets fell to $287.0 million from $326.6 million at the end of Q1, while retained earnings declined to negative $848.1 million because of accumulated losses.

  • Operating cash burn improved to $19.8 million in Q2 2026 from $25.3 million in Q1 and $27.6 million in Q2 2025.
  • Research and development expense was lower year over year, falling to $19.6 million from $26.9 million in Q2 2025.
  • Selling, general and administrative expense declined to $5.8 million, continuing a reduction from $7.8 million in Q2 2025 and $8.3 million in Q2 2024.
  • The company had no short-term debt at June 30, 2026 after repaying $126.4 million during Q1.
  • Cash, short-term investments and long-term investments totaled approximately $197.2 million, providing a meaningful source of funding for ongoing research and clinical programs.
  • Q2 investing cash flow was positive because investment maturities exceeded purchases; this improved liquidity but may not be repeatable.
  • Interest and investment income remained a source of support, contributing $2.0 million in Q2 2026, although this is dependent on the company’s investment balance and market yields.
  • IPSC reported no revenue in Q2 2026, and the company has not demonstrated recurring commercial revenue in the recent periods provided.
  • The quarterly net loss widened to $34.6 million from $21.6 million in Q1 2026, while other operating expenses rose to $11.1 million.
  • Weighted-average basic shares increased to approximately 205.8 million in Q2 2026 from 193.5 million in Q1 and 86.2 million in Q2 2025, signaling substantial dilution for existing shareholders.

Overall, IPSC’s balance sheet remains capable of supporting development activity, and lower core operating expenses and debt repayment are constructive trends. However, the investment case continues to depend heavily on clinical progress and future financing or partnership activity because the company has no recurring revenue and continues to consume cash.

10/14/26 01:59 PM ETAI Generated. May Contain Errors.

Century Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Century Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Century Therapeutics' net income appears to be on an upward trend, with a most recent value of -$9.58 million in 2025, rising from -$53.58 million in 2020. The previous period was -$126.57 million in 2024. Check out Century Therapeutics' forecast to explore projected trends and price targets.

Century Therapeutics' total operating income in 2025 was -$17.27 million, based on the following breakdown:
  • Total Gross Profit: $109.16 million
  • Total Operating Expenses: $126.43 million

Over the last 5 years, Century Therapeutics' total revenue changed from $0.00 in 2020 to $109.16 million in 2025, a change of 10,916,400,000.0%.

In the past 11 quarters, Century Therapeutics' cash and equivalents has ranged from $41.46 million in Q2 2024 to $56.88 million in Q2 2025, and is currently $49.64 million as of their latest financial filing in Q2 2026.

Century Therapeutics had total debt of $3.76 million at the end of 2025, compared with none in 2024, and a 61.0% decrease since 2020.

Over the last 5 years, Century Therapeutics' book value per share changed from -14.22 in 2020 to 1.82 in 2025.


Related Companies

Financial statements for NASDAQ:IPSC last updated on 8/12/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
INSANE DRONE FOOTAGE
New drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...
Paradigm Press | Sponsoredtc pixel
A new income category is drawing serious money - here's why
Forbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...
Investors Alley | Sponsoredtc pixel
Why Some AI Stocks Already Surged Over 300 Percent
Jason Bodner's system flagged Nvidia before a 7000 percent run, Super Micro Computer before a 2600 percent run...
Brownstone Research | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Trump To Relaunch USD?
President Trump's summit with Xi Jinping drew headlines for tariffs and trade truces, but the real story may b...
Porter & Company | Sponsoredtc pixel
The Iran War Isn’t Chaos. It’s Strategy.
Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...
Behind the Markets | Sponsoredtc pixel
Urgent: Invest In ‘Elon’s iPhone’ Before July 22nd
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel